Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy
Top Cited Papers
- 17 June 2008
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Pharmacological Reviews
- Vol. 60 (2), 196-209
- https://doi.org/10.1124/pr.107.07109
Abstract
Pharmacotherapy of central nervous system (CNS) disorders (e.g., neurodegenerative diseases, epilepsy, brain cancer, and neuro-AIDS) is limited by the blood-brain barrier. P-glycoprotein, an ATP-driven, drug efflux transporter, is a critical element of that barrier. High level of expression, luminal membrane location, multispecificity, and high transport potency make P-glycoprotein a selective gatekeeper of the blood-brain barrier and thus a primary obstacle to drug delivery into the brain. As such, P-glycoprotein limits entry into the CNS for a large number of prescribed drugs, contributes to the poor success rate of CNS drug candidates, and probably contributes to patient-to-patient variability in response to CNS pharmacotherapy. Modulating P-glycoprotein could therefore improve drug delivery into the brain. Here we review the current understanding of signaling mechanisms responsible for the modulation of P-glycoprotein activity/expression at the blood-brain barrier with an emphasis on recent studies from our laboratories. Using intact brain capillaries from rats and mice, we have identified multiple extracellular and intracellular signals that regulate this transporter; several signaling pathways have been mapped. Three pathways are triggered by elements of the brain9s innate immune response, one by glutamate, one by xenobiotic-nuclear receptor (pregnane X receptor) interactions, and one by elevated β-amyloid levels. Signaling is complex, with several pathways sharing common signaling elements [tumor necrosis factor (TNF) receptor 1, endothelin (ET) B receptor, protein kinase C, and nitric-oxide synthase), suggesting a regulatory network. Several pathways include autocrine/paracrine elements, involving release of the proinflammatory cytokine, TNF-α, and the polypeptide hormone, ET-1. Finally, several steps in signaling are potential therapeutic targets that could be used to modulate P-glycoprotein activity in the clinic.Keywords
This publication has 125 references indexed in Scilit:
- Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cellsJournal of Pharmacy and Pharmacology, 2007
- Blood–brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horsesJournal of Controlled Release, 2007
- Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann–Pick C diseaseProceedings of the National Academy of Sciences, 2006
- In Vivo Activation of Human Pregnane X Receptor Tightens the Blood-Brain Barrier to Methadone through P-Glycoprotein Up-RegulationMolecular Pharmacology, 2006
- Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and LipopolysaccharideMolecular Pharmacology, 2005
- Analysis of MDR1 haplotypes in Parkinson's disease in a white populationNeuroscience Letters, 2004
- Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanismLife Sciences, 2004
- Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoproteinEuropean Journal Of Cancer, 2004
- Pain and the blood–brain barrier: obstacles to drug deliveryAdvanced Drug Delivery Reviews, 2003
- The Nuclear Receptor PXR: A Master Regulator of “Homeland” DefenseCritical Reviews™ in Eukaryotic Gene Expression, 2002